Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 2 completion108d agoSohag University — ephedrine (Phase II Trial Completion)ephedrine

Therapy area: Cardiovascular. Indication: Hypotension

full page →ephedrine →source: globaldata

Apr 30, 2026phase 2 completion108d agoNational Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)metformin hydrochloride ER

Therapy area: Cardiovascular, Genito Urinary System, Infectious Disease. Indication: Acute Renal Failure (ARF) (Acute Kidney Injury), Sepsis, Septic Shock

full page →metformin hydrochloride ER →source: globaldata

Apr 30, 2026phase 2 completion108d agoAstraZeneca Plc — tozorakimab (Phase II Trial Completion)tozorakimab

Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

full page →tozorakimab →source: globaldata

Apr 30, 2026phase 2 completion108d agoCurtin University — influenza vaccine (Phase II Trial Completion)influenza vaccine

Therapy area: Cardiovascular. Indication: Myocardial Infarction

full page →influenza vaccine →source: globaldata

Apr 30, 2026phase 2 completion108d agoBeijing Sanbo Brain Hospital — ceritinib (Phase II Trial Completion)ceritinib

Therapy area: Oncology. Indication: Mesenchymal Tumor

full page →ceritinib →source: globaldata

Apr 30, 2026phase 2 completion108d agoWuhan Union Hospital — cadonilimab (Phase II Trial Completion)cadonilimab

Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)

full page →cadonilimab →source: globaldata

Apr 30, 2026phase 2 completion108d agoOhio State University Comprehensive Cancer Center — canakinumab (Phase II Trial Completion)canakinumab

Therapy area: Oncology. Indication: Lung Cancer

full page →canakinumab →source: globaldata

Apr 30, 2026phase 2 completion108d agoNational Cancer Institute US — ipilimumab (Phase II Trial Completion)ipilimumab

Therapy area: Oncology. Indication: Endometrial Cancer

full page →ipilimumab →source: globaldata

Apr 30, 2026phase 2 completion108d agoBioCanRx — ipilimumab (Phase II Trial Completion)ipilimumab

Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma

full page →ipilimumab →source: globaldata

Apr 30, 2026phase 2 completion108d agoChinese Academy of Medical Sciences and Peking Union Medical College — fuzuloparib (Phase II Trial Completion)fuzuloparib

Therapy area: Oncology. Indication: Soft Tissue Sarcoma

full page →fuzuloparib →source: globaldata

Apr 30, 2026phase 2 completion108d agoSun Pharmaceutical Industries Ltd — Absorica (Phase II Trial Completion)ISOTRETINOIN

Therapy area: Oncology. Indication: Neuroblastoma

full page →ISOTRETINOIN →source: globaldata

Apr 30, 2026phase 2 completion108d agoDutch Heart Foundation — ghrelin (Phase II Trial Completion)ghrelin

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Ischemic Stroke

full page →ghrelin →source: globaldata

Apr 30, 2026phase 2 completion108d agoHuadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)LIDOCAINE

Therapy area: Respiratory. Indication: Cough

full page →LIDOCAINE →source: globaldata

Apr 30, 2026phase 2 completion108d agoArcus Biosciences Inc — atezolizumab (Phase II Trial Completion)atezolizumab

Therapy area: Oncology. Indication: Prostate Cancer

full page →atezolizumab →source: globaldata

Apr 30, 2026phase 2 completion108d agoHospital Of Dalian Medical University 1 — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 2 completion108d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — capecitabine (Phase II Trial Completion)capecitabine

Therapy area: Oncology. Indication: Colorectal Cancer

full page →capecitabine →source: globaldata

Apr 30, 2026phase 2 completion108d agoNanfang Hospital of Southern Medical University — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Small-Cell Lung Cancer

full page →adebrelimab →source: globaldata

← prev

page 5 of 5

Week of Apr 27, 2026